ARTICLE | Company News
Roche (SIX:ROG; OTCQX:RHHBY) is exercising its option to acquire Versant Venture’s remyelination play Inception 5 Inc. (San Diego, Calif.). Concurrently, the VC is doubling down on regenerative therapies for neurology through the launch of successor company Pipeline Therapeutics Inc., which has ambitions in and beyond remyelination.
Inception 5 was spun out of Versant’s small molecule discovery engine Inception Sciences Inc. (San Diego, Calif.) in a 2014 build-to-buy deal with Roche. Versant provided equity financing while Roche gave funds for research. The financial terms of the deal remain undisclosed (see BioCentury, June 30, 2014)...